{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:02:55Z","timestamp":1792735375767,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.clon.2021.07.008","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T01:41:21Z","timestamp":1627695681000},"page":"e553-e560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dose-dense Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy for Stage IIB\/IIIA Non-small Cell Lung Cancer \u2013 A Phase II trial"],"prefix":"10.1016","volume":"33","author":[{"given":"A.","family":"Mittal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.S.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chitikela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bharti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Thulkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2021.07.008_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clon.2021.07.008_bib2","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/GO.20.00122","article-title":"ICMR-NCDIR-NCRP Investigator Group. Cancer Statistics, 2020: Report From National Cancer Registry Programme, India","volume":"6","author":"Mathur","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.clon.2021.07.008_bib3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7314\/APJCP.2013.14.1.489","article-title":"Clinico-pathological profile of lung cancer at AIIMS: a changing paradigm in India","volume":"14","author":"Malik","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.clon.2021.07.008_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fonc.2018.00005","article-title":"Before or after: evolving neoadjuvant approaches to locally advanced non-small cell lung cancer","volume":"8","author":"Lewis","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2021.07.008_bib5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.21037\/qims.2018.08.02","article-title":"The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications","volume":"8","author":"Lim","year":"2018","journal-title":"Quant Imag Med Surg"},{"key":"10.1016\/j.clon.2021.07.008_bib6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1586\/14737140.2014.867809","article-title":"Controversies in the management of stage III non-small-cell lung cancer","volume":"14","author":"Biswas","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"10.1016\/j.clon.2021.07.008_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.21037\/atm.2020.01.129","article-title":"Recommended changes for the 8th edition of the TNM classification for lung cancer \u2013 the findings of a single-institution evaluation","volume":"8","author":"Wang","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clon.2021.07.008_bib8","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.athoracsur.2014.05.070","article-title":"Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer","volume":"98","author":"Lou","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.clon.2021.07.008_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2021.07.008_bib10","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/S0959-8049(03)00319-8","article-title":"Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. An EORTC phase II study (EORTC 08958)","volume":"39","author":"O'Brien","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2021.07.008_bib11","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1200\/JCO.2005.55.405","article-title":"Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol","volume":"23","author":"Belani","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2021.07.008_bib12","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1200\/JCO.2008.16.4855","article-title":"Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non\u2013small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups","volume":"26","author":"Strauss","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2021.07.008_bib13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/bcr1007","article-title":"Dose-dense adjuvant chemotherapy for primary breast cancer","volume":"7","author":"Fornier","year":"2005","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clon.2021.07.008_bib14","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2021.07.008_bib15","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2021.07.008_bib16","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2021.07.008_bib17","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(19)32259-7","article-title":"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial","volume":"394","author":"Clamp","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2021.07.008_bib18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2021.07.008_bib19","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.2007.13.1912","article-title":"Randomized phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer","volume":"26","author":"Belani","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2021.07.008_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2021.07.008_bib21","first-page":"925","article-title":"Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer","volume":"28","author":"Crawford","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clon.2021.07.008_bib22","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1097\/JTO.0b013e3181b9ecca","article-title":"Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials","volume":"4","author":"Lim","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2021.07.008_bib23","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/0003-4975(93)91072-U","article-title":"Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients","volume":"55","author":"Martini","year":"1993","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"10.1016\/j.clon.2021.07.008_bib24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/cncr.11460","article-title":"Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable stage IIIA-bulky N2 and stage IIIB non-small cell lung carcinoma","volume":"98","author":"Cappuzzo","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2021.07.008_bib25","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ejca.2006.01.049","article-title":"Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer (EORTC 08984)","volume":"42","author":"Biesma","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2021.07.008_bib26","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1200\/JCO.2007.12.0014","article-title":"Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901","volume":"25","author":"Garrido","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2021.07.008_bib27","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11670-006-0218-3","article-title":"Effect of neoadjuvant chemotherapy using paclitaxel combined with carboplatin on advanced non-small cell lung cancer","volume":"18","author":"Xiong","year":"2006","journal-title":"Chin J Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.clon.2021.07.008_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.e20501","article-title":"Weekly nab-paclitaxel plus carboplatin as neoadjuvant therapy for IIIA-N2 lung squamous cell carcinoma: a prospective phase II study","volume":"36","author":"Zhu","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2021.07.008_bib29","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1097\/JTO.0b013e3182209043","article-title":"Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University Oncology Group phase II study","volume":"6","author":"Ahmed","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2021.07.008_bib30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clon.2017.11.001","article-title":"Practice patterns and outcomes for pemetrexed plus platinum doublet as neoadjuvant chemotherapy in adenocarcinomas of lung: looking beyond the usual paradigm","volume":"30","author":"Noronha","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2021.07.008_bib31","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/JTO.0000000000000062","article-title":"Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer","volume":"9","author":"Dy","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2021.07.008_bib32","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/cncr.29800","article-title":"Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001)","volume":"122","author":"Ou","year":"2016","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.clon.2021.07.008_bib33","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jnci\/djk093","article-title":"European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer","volume":"99","author":"van Meerbeeck","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clon.2021.07.008_bib34","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clon.2021.07.008_bib35","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2021.07.008_bib36","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655521002673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655521002673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:50:11Z","timestamp":1760543411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655521002673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0936655521002673"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2021.07.008","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-dense Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy for Stage IIB\/IIIA Non-small Cell Lung Cancer \u2013 A Phase II trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2021.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}